University of California San Francisco
Helen Diller Family Comprehensive Cancer Center
Sandy W. Wong, MD

Sandy W. Wong, MD

Assistant Clinical Professor, Division of Hematology/Oncology, UCSF

Cancer Center Program Memberships

Hematopoietic Malignancies

Education

Brown University, BA, 5/2003, Human Biology
University of Massachusetts Medical School, MD, 5/2009, Medicine
Tufts Medical Center, 6/2012, Internal Medicine Residency
Tufts Medical Center, 6/2016, Hematology/Oncology Fellowship
Tufts Medical Center, 6/2016, Amyloidosis Fellowship


Professional Experience

  • 2012-2013
    Assistant Professor, Department of Medicine, Tufts University School of Medicine, Boston, MA
  • 2016 - present
    Assistant Clinical Professor, Division of Hematology/Oncology, UCSF, San Francisco, CA

Honors & Awards

  • 2012
    Medicine Resident of the Year, Tufts Medical Center, Department of Medicine
  • 2016
    Chan Soon-Shiong Fellow, Tufts Medical Center, Division of Hematology/Oncology

Selected Publications

  1. Shah EE, Young RP, Wong SW, Damon LE, Wolf JL, Shah ND, Leavitt AD, Loeffler P, Martin TG. Impact of Plerixafor Use at Different Peripheral Blood CD34+ Thresholds on Autologous Stem Cell Collection in Patients with Multiple Myeloma. Biol Blood Marrow Transplant. 2019 Nov 27.
    View on PubMed
  2. Swetha Kambhampati, Derek Galligan, Guy Ledergor, Thomas G. Martin, Jeffrey Wolf, Sandy W. Wong, Nina D. Shah. A Single-Center Retrospective Cohort Analysis of Venetoclax in Relapsed/Refractory Multiple Myeloma. Blood. 2019 Nov 13; 134(Supplement_1):5576-5576.
    View on PubMed
  3. Aparna Raval, Hearn Jay Cho, Cherie Green, Elisabeth Wassner Fritsch, Connie Ma, Naomi Chang, Mark Yan, Mark Kockx, Shine Shen, Ling-Yuh Huw, Emily Balestiere, Marina Lipkind, Huang Huang, Michelle Byrtek, Dawn Colburn, Sandy W. Wong, Jeffrey M. Venstrom, Joanne I Adamkewicz. Dynamics of Activated CD8+ T-cells and Decreased Osteoclasts in the Tumor Microenvironment are Associated with Clinical Efficacy of Anti-PD-L1 and Anti-CD38 Combination Treatment in Relapsed or Refractory Multiple Myeloma. Blood. 2019 Nov 13; 134(Supplement_1):1907-1907.
    View on PubMed
  4. Kyle Roter, Donglei Hu, Alyssa Clay-Gilmour, Scott Huntsman, Nina D. Shah, Sandy W. Wong, Thomas G. Martin, Jeffrey Lee Wolf, Moritz Binder, Shaji K. Kumar, S. Vincent Rajkumar, Susan L. Slager, Celine M. Vachon, Elad Ziv. Germline Variation Predicts Treatment Response in Multiple Myeloma. Blood. 2019 Nov 13; 134(Supplement_1):4397-4397.
    View on PubMed
  5. Ian Ferguson, Yu-Hsiu T. Lin, Sami Tuomivaara, Jeffrey L. Wolf, Thomas G. Martin, Sandy W. Wong, Nina D. Shah, Christoph Driessen, Brian G. Van Ness, Arun P. Wiita. Profiling the Cell Surface Landscape of Proteasome Inhibitor-Treated and -Resistant Multiple Myeloma to Guide Immunotherapy Targeting, Diagnosis, and Biology. Blood. 2019 Nov 13; 134(Supplement_1):1803-1803.
    View on PubMed
  6. Choudhry P, Mariano MC, Geng H, Martin TG, Wolf JL, Wong SW, Shah N, Wiita AP. DNA methyltransferase inhibitors upregulate CD38 protein expression and enhance daratumumab efficacy in multiple myeloma. Leukemia. 2019 Oct 08.
    View on PubMed
  7. Swetha Kambhampati, Derek Galligan, Nina Shah, Jeffrey Wolf, Sandy Wong, Thomas Martin. A single-center retrospective cohort analysis of venetoclax in relapsed/refractory multiple myeloma. Clinical Lymphoma Myeloma & Leukemia. 2019 Oct 1; 19(10):e261.
    View on PubMed
  8. Guy Ledergor, Elizabeth McCarthy, Nina Shah, Sandy Wong, Hewitt Chang, Frances Fan, Evans Shao, Lissa Gray, Alexander Cheung, Serena Kwek, Sophia Bylsma, Samuel Del Favero, Rosanna Wustrack, Matthew Spitzer, Jeffrey Wolf, Thomas Martin, Jimmie Ye, Lawrence Fong. Single cell Dissection of Resistance to anti-BCMA CAR-T cell Therapy. Clinical Lymphoma Myeloma & Leukemia. 2019 Oct 1; 19(10):e25-e26.
    View on PubMed
  9. Mikhael J, Ismaila N, Cheung MC, Costello C, Dhodapkar MV, Kumar S, Lacy M, Lipe B, Little RF, Nikonova A, Omel J, Peswani N, Prica A, Raje N, Seth R, Vesole DH, Walker I, Whitley A, Wildes TM, Wong SW, Martin T. Treatment of Multiple Myeloma: ASCO and CCO Joint Clinical Practice Guideline. J Clin Oncol. 2019 May 10; 37(14):1228-1263.
    View on PubMed
  10. Huang LW, Wong SW, Andreadis C, Olin RL. Updates on Hematologic Malignancies in the Older Adult: Focus on Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, and Multiple Myeloma. Curr Oncol Rep. 2019 Mar 08; 21(4):35.
    View on PubMed
  11. Derek Galligan, Rupa Narayan, Sarah Kim, Ann Lazar, Marisela Tan, Richard Fong, Mimi Lo, Nina Shah, Shagun Arora, Sandy W. Wong, Thomas G. Martin, Jeffrey Lee Wolf. Retrospective Analysis of Modified Hyper-CVAD Therapy Combined with Proteasome Inhibition for Patients with Multiple Myeloma and Renal Insufficiency or Renal Failure. Blood. 2018 Nov 29; 132(Supplement 1):3236-3236.
    View on PubMed
  12. Ma X, Wong SW, Zhou P, Chaulagain CP, Doshi P, Klein AK, Sprague K, Kugelmass A, Toskic D, Warner M, Miller KB, Lee L, Varga C, Comenzo RL. Daratumumab binds to mobilized CD34+ cells of myeloma patients in vitro without cytotoxicity or impaired progenitor cell growth. Exp Hematol Oncol. 2018; 7:27.
    View on PubMed
  13. Wong SW, Hegenbart U, Palladini G, Shah GL, Landau HJ, Warner M, Toskic D, Jaccard A, Hansen T, Bladé J, Cibeira MT, Kastritis E, Dispenzieri A, Wechalekar A, Varga C, Schönland SO, Comenzo RL. Outcome of Patients With Newly Diagnosed Systemic Light-Chain Amyloidosis Associated With Deletion of 17p. Clin Lymphoma Myeloma Leuk. 2018 11; 18(11):e493-e499.
    View on PubMed
  14. Tan M, Kalin-Hajdu E, Narayan R, Wong SW, Martin TG. Zoledronic acid-induced orbital inflammation in a patient with multiple myeloma. J Oncol Pharm Pract. 2019 Jul; 25(5):1253-1257.
    View on PubMed
  15. Ajai Chari, Joshua Ryan Richter, Nina Shah, Sandy Wai Kuan Wong, Sundar Jagannath, Hearn J. Cho, Noa Biran, Jeffrey Wolf, Samir S. Parekh, Pamela N. Munster, Deepu Madduri, Frank Campana, Thomas G. Martin. Phase I-b study of isatuximab + carfilzomib in relapsed and refractory multiple myeloma (RRMM). Journal of Clinical Oncology. 2018 May 20; 36(15_suppl):8014-8014.
    View on PubMed
  16. Lam C, Ferguson ID, Mariano MC, Lin YT, Murnane M, Liu H, Smith GA, Wong SW, Taunton J, Liu JO, Mitsiades CS, Hann BC, Aftab BT, Wiita AP. Repurposing tofacitinib as an anti-myeloma therapeutic to reverse growth-promoting effects of the bone marrow microenvironment. Haematologica. 2018 07; 103(7):1218-1228.
    View on PubMed
  17. Eshana E. Shah, Rebecca Young, Sandy W. Wong, Thomas G. Martin. 192 Impact of Plerixafor Use at Different Peripheral Blood CD34+ Cell Thresholds on Autologous Stem Cell Collection in Patients with Multiple Myeloma. Biology of Blood and Marrow Transplantation. 2018 Mar 1; 24(3):s176-s177.
    View on PubMed
  18. Derek Galligan, Nina Shah, Jeffrey Wolf, Sandy Wong, Linda Abramovitz, Brenn Donnelly, Rupa Narayan, Gabriel Mannis, Shagun Arora, Amy Marsala, Miguel Cerejo, Thomas Martin. A Single-Center Retrospective Cohort Analysis of Venetoclax in Relapsed/Refractory Multiple Myeloma. Clinical Lymphoma Myeloma & Leukemia. 2017 Sep 1; 17:s339.
    View on PubMed
  19. Wong SW, Toskic D, Warner M, Varga C, Moreno-Koehler A, Fein D, Fogaren T, Lee L, Oliver CM, Guthrie SD, Comenzo RL. Primary Amyloidosis With Renal Involvement: Outcomes in 77 Consecutive Patients at a Single Center. Clin Lymphoma Myeloma Leuk. 2017 11; 17(11):759-766.
    View on PubMed
  20. Derek Galligan, Nina Shah, Jeffrey Lee Wolf, Sandy Wai Kuan Wong, Linda Abramovitz, Brenn Donnelly, Rupa Narayan, Gabriel N. Mannis, Shagun D. Arora, Thomas G. Martin. A single-center retrospective cohort analysis of venetoclax in post-transplant, relapsed/refractory multiple myeloma. Journal of Clinical Oncology. 2017 May 20; 35(15_suppl):e19514-e19514.
    View on PubMed

Go to UCSF Profiles, powered by CTSI